Nada, A., Ata, L., Amer, A., Elabd, N. (2022). Impact of long-term eradication of chronic Hepatitis C infection using the direct-acting antiviral treatment on liver fibrosis parameters in Egyptian patients. Medical Journal of Viral Hepatitis, 7.1(1), 21-32. doi: 10.21608/mjvh.2022.279334
Ali Nada; Lmyaa Ata; Amany A. Amer; Naglaa S. Elabd. "Impact of long-term eradication of chronic Hepatitis C infection using the direct-acting antiviral treatment on liver fibrosis parameters in Egyptian patients". Medical Journal of Viral Hepatitis, 7.1, 1, 2022, 21-32. doi: 10.21608/mjvh.2022.279334
Nada, A., Ata, L., Amer, A., Elabd, N. (2022). 'Impact of long-term eradication of chronic Hepatitis C infection using the direct-acting antiviral treatment on liver fibrosis parameters in Egyptian patients', Medical Journal of Viral Hepatitis, 7.1(1), pp. 21-32. doi: 10.21608/mjvh.2022.279334
Nada, A., Ata, L., Amer, A., Elabd, N. Impact of long-term eradication of chronic Hepatitis C infection using the direct-acting antiviral treatment on liver fibrosis parameters in Egyptian patients. Medical Journal of Viral Hepatitis, 2022; 7.1(1): 21-32. doi: 10.21608/mjvh.2022.279334
Impact of long-term eradication of chronic Hepatitis C infection using the direct-acting antiviral treatment on liver fibrosis parameters in Egyptian patients
1Hepatology Gastroenterology Department, National liver institute, Menoufia University, Menoufia, Egypt
2Tropical Medicine Department, Faculty of Medicine, Menoufia University, Menoufia, Egypt
Abstract
Background: Hepatitis C virus (HCV) treatment aims to halt the progression of fibrosis and reducing its complications. HCV-treatment has been enhanced by the development of all-oral DAAs with good efficacy and a reasonable side effect. Aims: The goal of this study is to see how long-term eradication of HCV affect liver fibrosis following DAAs therapy. Materials and methods: 500 HCV patients receiving sofosbuvir-based therapy with daclatasvir or ledipasvir (with or without ribavirin). In addition to clinical, laboratory, and radiological examination, FIB-4, APRI, Fibroscan examination, Child and MELD scores were calculated at baseline and one year after end of therapy (EOT). Results: Out of 500 participants included in the study, 493 participants complete the study period. 454 (92.1%) patients had sustained virologic response (SVR) during the period of study and 39 patients were non-responders. In patients with SVR, FIB-4 index, APRI score and fibroScan measures showed significant reduction one-year post-EOT versus baseline (p < 0.001 for all). Although, Child score in patients had SVR did not demonstrate a significant improvement one year after EOT versus baseline (p = 0.479), it showed a significant improvement versus non responder (p < 0.001). In addition, MELD score revealed a significant reduction in patients who achieved SVR one-year post-EOT versus baseline (p = 0.028). Furthermore, one-year following EOT, there was a significant improvement in MELD score in patients with SVR versus non-responder (p < 0.001). Conclusion: DAAs therapy in HCV-related liver disease had a good impact on liver fibrosis regression and the improvement of its outcome.
View on SCiNiTO
Top